The role of scavenger receptor class B, type I (SR-BI) in lipoprotein metabolism has been studied widely (1) . Initially identified for its ability to bind oxidized LDL (2), SR-BI was subsequently shown to be the first molecularly defined receptor that can mediate the selective uptake of cholesteryl ester (CE) from HDL (3) and LDL (4, 5) into cells. SR-BI resides in the plasma membrane of cells and is composed of a glycosylated extracellular domain and two membrane-spanning domains near the N-and C-terminal regions of the molecule (6, 7) . Comparison of SR-BI to a closely related scavenger receptor, CD36, shows that while both receptors can mediate binding of HDL, only SR-BI is efficient at promoting selective CE uptake, and this function is attributable directly to the extracellular domain of SR-BI (8, 9) . Also, mutational analysis of this region of the receptor revealed two arginine residues that may be important for efficient uptake of CE from HDL (10) . More recently, it was shown that the unique ability of SR-BI to mediate selective lipid uptake does not require accessory proteins or structural components of the cell membrane (11) , although a PDZ domain protein appears to be required for the receptor to properly translocate to the plasma membrane in hepatocytes in vivo (12) .
The most widely studied ligands for SR-BI are the serum lipoproteins, in particular HDL, due to its participation in reverse cholesterol transport (13, 14) . A range of ligands besides lipoproteins has been identified, including anionic phospholipids (15) , advanced glycation end products (16) , and apoptotic cells (17) . Both the protein and lipid components of HDL can bind to SR-BI, but the selective uptake of lipids into the cell requires protein-protein interaction between the lipoprotein and the receptor since phospholipid vesicles and lipid emulsion particles devoid of apolipoproteins cannot mediate selective uptake (18) . Instead, apolipoprotein-free lipid particles seem to fuse with the cell membrane after interaction with SR-BI (18) . One model of SR-BI-mediated selective lipid uptake mechanism invokes formation of a hydrophobic channel between the bound lipoprotein particle and the cell membrane (19) , while another invokes a hemifusion process (9) . Regardless of the mechanism, it is clear that there is a high correlation between lipoprotein binding and the selective uptake of lipids consistent with SR-BI-mediated lipid uptake involving the two sequential steps of lipoprotein particle binding and lipid uptake (8, 9, 19, 20) . With regard to efflux of cholesterol from cells, it is still controversial whether binding to the receptor is an absolute requirement for the process. There is a report that provides evidence that SR-BI-dependent efflux of cholesterol requires a productive binding of the extracellular lipid acceptor (21) , while another study shows that binding of liposomal acceptors to SR-BI is not necessary (22) .
Clearly, a molecular understanding of the lipid selective uptake process requires that the interactions of apolipoproteins with SR-BI be characterized thoroughly. The initial study (23) demonstrated that individual HDL apolipoproteins (apoA-I, apoA-II, and apoC-III), reconstituted into HDL particles, bind to SR-BI. Subsequent work with apoA-I has shown that its conformation is important for receptor interaction. Thus, conformational changes induced by adding different amounts of phospholipid to create HDL particles of different sizes alter the affinity of binding to SR-BI (24, 25) . The apoA-I/SR-BI interaction is complex in that there is not a unique recognition site in the apolipoprotein because domains in both the N-and C-terminal regions of the molecule can mediate binding (26) . Apparently, N-and C-terminal regions can both bind because they contain an amphipathic ␣ -helix that is a recognition motif for SR-BI (26) . The interactions of apoA-II and apoE with SR-BI are less well understood, and contradictory results have been published. Thus, it has been reported that the presence of apoA-II together with apoA-I in HDL particles can either increase (27) or decrease (20) binding to SR-BI. In the case of apoE, it has been claimed recently that apoE/phospholipid complexes can (18, 28) and cannot (29) bind to SR-BI. Furthermore, contrary to the situation with apoA-I (25), it is reported that lipidation of apoE reduces its ability to bind to the receptor (29) .
The purpose of this study is to provide new quantitative information and to clarify some of the discrepancies concerning the binding of apolipoproteins to SR-BI. We find that apoA-I, apoA-II, and apoE in the lipid-free state lack the ability to fully compete for HDL binding to SR-BI. However, once these apolipoproteins are associated with phospholipids, they all demonstrate similar abilities to compete fully for the binding of HDL to SR-BI. Results using various domains of apoA-I and apoE and synthetic peptides show that the SR-BI/apolipoprotein interaction is not amino acid sequence specific, but that the class of amphipathic ␣ -helix affects the binding.
EXPERIMENTAL PROCEDURES

Materials
1,2-Dimyristoyl phosphatidylcholine (DMPC) and 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC) were purchased from Avanti Polar Lipids (Albaster, AL). Carrier-free 125 I-Na (15 Ci/ mg) was purchased from New England Nuclear (Boston, MA). Ham's F-10 and minimal essential media for tissue culture were purchased from Bio Whittaker (Walkersville, MD). Bovine serum albumin, horse serum, and fetal bovine serum were purchased from Sigma (St. Louis, MO). Cortrosyn, a synthetic analog of adrenocorticotropic hormone, was purchased from Organon (West Orange, NJ).
Human HDL was isolated from normolipidemic donors by sequential ultracentrifugation (30) . ApoA-I and apoA-II were isolated from human HDL as described (31) . Prior to use, the purified apolipoproteins were resolubilized in 6 M guanidine hydrochloride (GdnHCl) and dialyzed against Tris-buffered saline (TBS) (10 mM Tris, 150 mM NaCl, 0.1 mM EDTA; pH 7.4). Human apoE isoforms were expressed in Escherichia coli and purified according to the method of Morrow et al. (32) ; apoE samples were solubilized in 6 M GdnHCl and 1% ␤ -mercaptoethanol, and dialyzed extensively against 100 mM ammonium bicarbonate buffer prior to use. Synthetic peptides of human apoA-I were synthesized using an automated solid-phase peptide synthesizer as described (33) . The peptides were blocked at the N-and C-terminal and corresponded to amino acid residues 1-43, 44-65, 44-87, and 209-241 of apoA-I with molecular masses of 4,824, 2,438, 5,087, and 3,749 Da, respectively. The amphipathic ␣ -helical peptides L-18A (DWLKAFYDKVAEKLKEAF), D-18A (18A sequence but containing d amino acids), L-37pA (18A-proline-18A), D-37pA, and DL-37pA (D-18A-proline-L-18A; the proline separating the two 18A segments was the L form) have been described before (34) and were prepared in a similar way; the molecular masses of the 18A peptides (which were N-and C-terminal blocked) and 37pA were 2,243 Da and 4,483 Da, respectively. Concentrations for the peptides were determined from the absorbance at 280 nm using the following molar absorbtivities: 8,250, 5,690, 11,380, 1,280, 13,940, and 6,970 M Ϫ 1 cm Ϫ 1 for apoA-I peptides 1-43, 44-65, 44-87, 209-241, the 18A peptide, and the 37pA peptide, respectively. As necessary, HDL and apolipoproteins were labeled with 125 I using the iodine monochloride method (35) ; the specific activities of the labeled products were in the range of 300 to 1,500 dpm/ng protein.
Cyanogen bromide fragments of apoA-I
Human apoA-I was subjected to fragmentation at three internal methionine residues using cyanogen bromide (CNBr), as described by Morrison et al. (36) ; the peptides were purified by HPLC. Briefly, 30 mg of apoA-I was digested with 3 ml of CNBr in 70% trifluoroacetic acid (TFA) for 24 h. The reaction was terminated by the addition of deionized water, after which the reaction mixture was lyophilized and subjected to reversed-phase HPLC (VYDAC 22 mm inner diameter ϫ 25 cm, particle size 10 m) using an acetonitrile-water (containing 0.1% TFA) solvent system with a gradient of 0% to 60% acetonitrile for 90 min at a rate of 5 ml per min. Fractions at retention times 55.3 min, 57 min, 62 min, 65 min, and 68 min corresponding to fragments 1, 2, 3, 4, and 5, respectively, were collected. The samples were lyophilized and characterized using an analytical HPLC and mass spectral analysis using a PE-Sciox APT-III triple-quadrupole ion spray mass spectrometer (MS core facility at UAB-Birmingham). samples of interest were the 9,880 Da fragment corresponding to the N-terminus and the 10,700 Da fragment corresponding to the C-terminus of apoA-I. The lyophilized samples were dissolved in TBS and the concentrations determined from the absorbance at 280 nm using the extinction coefficients 2.04 and 0.45 for 1 mg/ml solutions of the N-and C-terminal peptides, respectively.
Preparation of small unilamellar vesicles
The method of Barenholz et al. (37) was adapted to prepare small unilamellar vesicles (SUVs). POPC was dissolved in chloroform-methanol (1:1, v/v) and dried under nitrogen onto the wall of a glass tube and placed in a vacuum oven to completely remove any remaining solvent. To form multilamellar vesicles (MLVs), the lipid was then rehydrated in TBS. This dispersion was sonicated on ice under nitrogen using a tapered titanium tip (Branson Sonifier 350) for 5 min followed by 1 min of cooling. The initially cloudy lipid mixture became translucent after this cycle was repeated 10 times. Thereafter, the sample was centrifuged in a Beckman 50 Ti rotor for 2 h at 4 Њ C at 145,000 g to remove the titanium debris that was produced during the sonication, and to separate any remaining MLV from the small SUV layer. The top SUV layer was removed and used in competitive binding experiments.
Discoidal reconstituted HDL preparation and characterization
Discoidal reconstituted HDL (rHDL) complexes containing DMPC and apoA-I (2:1, w/w) were prepared by incubating the lipid-protein solution at the phase transition temperature of DMPC, 24 Њ C. The appropriate amount of phospholipid dissolved in chloroform-methanol (1:1, v/v) was dried on the wall of a glass tube with nitrogen and allowed to dry completely in a vacuum oven. The dried lipid was then dissolved in TBS to form MLV. After equilibration in a 24 Њ C water bath, the lipid and apoA-I solutions were mixed and further incubated in the same water bath for 30 min, at which time the initially turbid lipid-protein solution became clear. Under the experimental conditions used, there was essentially quantitative incorporation of protein into the lipid-protein complexes; formation of the complexes was assessed by analysis using nondenaturing 8-25% gradient electrophoresis gels (Amersham-Pharmacia). Similar discoidal complexes of apoA-II, apoE isoforms and the various peptides (38) were prepared in the same fashion. Additionally, some rHDL particles were prepared by using DMPC-SUV and cycling the lipid-protein mixture across the phase transition temperature of DMPC. This was accomplished by cycling the lipid-protein solution at 10 Њ C for 10 min followed by 10 min at 37 Њ C several times. Results of experiments using rHDL prepared by direct incubation of apolipoprotein with either MLV or SUV were similar.
Cell culture experiments
Y1-BS1 murine adrenal cells were grown in Ham's F-10 medium (supplemented with 12.5% horse serum, 5% fetal bovine serum, and 50 g/ml of gentamycin) in a humidified 5% CO 2 incubator at 37 Њ C as described before (19) . For experiments, Y1-BS1 adrenal cells were seeded in 12 or 24 well tissue culture flasks and allowed to grow for 2 to 3 days until ‫ف‬ 75% to 80% confluency was reached. The cells were then stimulated for 24 h with 100 nM cortrosyn (dissolved as a 100 mM stock solution in PBS) in serum-free Ham's F-10 medium to increase the expression of SR-BI protein. Immunoblot analysis confirmed the increased expression of SR-BI upon stimulation with hormone (data not shown). For competitive binding experiments, the monolayer was washed twice with serum-free Ham's F-10 medium (at 4 Њ C) and then equilibrated at 4 Њ C. Subsequently, 10 g protein/ml of 125 I-HDL 3 plus increasing amounts of the unlabeled competitor in serum-free medium were incubated with the cell monolayer for 2 h at 4 Њ C. Control wells were also included that contained only 125 I-HDL 3 and no competitor. After the incubation, the cell monolayer was washed three times with 2 ml of ice-cold PBS containing 0.1% BSA plus one additional wash with 2 ml of PBS alone, then 0.1 N NaOH was used to solubilize the cell monolayer. Aliquots of this lysate were taken to determine the cell-associated 125 I in a ␥ counter, and the protein content was measured using a modified Lowry method (39) . HDL binding and selective CE uptake were measured as described previously (19) .
Control experiments were conducted to establish that incubation of 125 I-HDL 3 with unlabeled competitor did not lead to displacement of 125 I-apolipoprotein from the HDL particle. We incubated 125 I-HDL 3 with a 10-fold excess of unlabeled apoA-I for 2 h at 4 Њ C, and passed the mixture over a gel-filtration column (Pharmacia Superdex 200, 1.6 ϫ 60 cm). Displaced 125 I-apolipoprotein was not detected in the fractions that contained lipidfree apoA-I, and the specific activity of the 125 I-HDL 3 did not decrease by more than 5% (data not shown). To examine further the ability of apolipoproteins to exchange from human HDL 3 , the apolipoproteins on the lipoprotein particle were labeled by reductive methylation using [ 14 C]formaldehyde. HDL 3 labeled in this fashion was incubated with excess human VLDL (the VLDL-HDL phospholipid ratio was 10:1, v/v) at 37 Њ C, and the VLDL was rapidly precipitated at different times by the addition of manganese phosphate. About 10% of the radiolabeled apolipoprotein transferred to VLDL within 1 min, but there was no further detectable transfer over a 24 h period. It follows that Ͻ 10% of the labeled apoA-I on HDL 3 particles is available for transfer to excess lipoprotein particles under the conditions of the competitive binding assay used in this study. Consequently, the reductions in the amount of 125 I-HDL 3 associated with cells when 125 I-HDL 3 was presented together with an unlabeled competitor were due to competition for binding to SR-BI and are not due to displacement of 125 I-apolipoprotein from HDL 3 in the extracellular medium. In the above experiments, care was taken to ensure that the effective concentration of the ligands in the incubation medium was accurate by preventing any loss of sample through binding to the polypropylene tube used for mixing the 125 I-HDL 3 and competitors. This was accomplished by prerinsing the polypropylene tubes with a 10% BSA solution, washing with deionized water, and completely removing any trace of liquid from the tubes prior to use. In addition, freshly dialyzed samples (stored in 6M GdnHCl) of lipid-free apolipoproteins were used to ensure that the proteins were not significantly self-associated and were available to compete for binding to SR-BI. To confirm this, control experiments were performed by cross-linking the apolipoproteins at various concentrations using bis(sulfosuccinimidyl)suberate (40) . At least up to 0.5 mg/ml lipid-free apoA-I, apoA-II, and the apoE3-22 kDa fragments were monomeric; apoE-3 existed mostly as monomers, but some tetramers were present under these conditions. For apoE isoforms, the storage buffer also contained 1% ␤ -mercaptoethanol to prevent inter-and intramolecular disulfide bonds from forming.
Data analysis
Direct binding of ligand to cells was analyzed using a nonlinear regression fitting to Eq. 1
on Graph Pad Prism as described before (19) . The results of the competitive binding experiments were analyzed using the logit February 23, 2013 www.jlr.org Downloaded from transformation (41) . The parameter of interest is the IC 50 , which is the concentration of the competitor ligand required to reduce the binding of 125 I-HDL 3 by 50%. To obtain the IC 50 values most accurately, the competitor concentration was transformed to the logarithmic scale, and the amount of 125 I-HDL 3 bound to the SR-BI was expressed as logit (B) ϭ ln B/(100-B) where B is the percent 125 I-HDL 3 bound to the cell. The IC 50 is the concentration of competitor when B ϭ 50 or logit B ϭ 0; this value was determined using linear regression analysis (Graph Pad Prism). Differences between the various competitors of 125 I-HDL 3 binding were tested for statistical significance by using a nonparametric t -test (significance was set at an ␣ value of 0.05). The IC 50 values listed in Table 1 were obtained by averaging multiple competition experiments. The errors in the IC 50 values were derived from the linear regression analysis and were within no more than 10% of the mean in each case. The Hill slope for 125 I-HDL 3 versus HDL binding was obtained using the sigmoidal dose-response variable slope equation (Eq. 2) on Graph Pad Prism:
RESULTS
Competitive binding of HDL Our goal in this study was to provide more information regarding the first step of the SR-BI-mediated uptake of HDL lipids into cells. This two-step process involves the reversible binding of the lipid donor particle to SR-BI and the subsequent movement of the lipid to the cell membrane (see Appendix). Direct binding of HDL to Y1-BS1 cells involves both high-affinity, low-capacity (SR-BI) and low-affinity, high-capacity components (nonspecific binding) (19, 42) . The high-affinity HDL binding to SR-BI and the associated CE selective uptake obtained by nonlinear regression analysis (see Experimental Procedures) are shown in Fig. 1 . It is evident from the figure that the binding of a lipid donor particle, in this case HDL, is tightly correlated (r 2 To compare the relative affinities of the various exchangeable apolipoproteins of HDL, we employed competitive binding experiments, with HDL as the labeled ligand. Experiments were conducted at 4ЊC to minimize cellular uptake and degradation of ligands through endocytosis. Figure 2 shows the competitive binding of 125 I-HDL 3 versus unlabeled HDL 3 . As expected, HDL 3 competes effectively with 125 I-HDL 3 ; note that 80-85% of 125 I-HDL 3 binding is inhibited at concentrations of unlabeled HDL 3 Ͼ 300 g protein/ml. The lack of complete inhibition is likely due to a combination of nonsaturable nonspecific binding of the radiolabeled ligand to the cell and to the plastic tissue culture plates. In Fig. 2B , the competitive binding data from Fig. 2A was transformed by taking the log of the competitor d Phospholipid-to-protein mass ratio was 2:1. . The high-affinity binding (square) and selective CE uptake (triangle) were determined as described before (19) . The data are the mean Ϯ SD from two experiments, with triplicate wells in each experiment (n ϭ 6). Fig. 2C . Several competitive binding experiments were combined, and the concentration of the competitor was logarithmically transformed and plotted against the binding of the 125 I-HDL 3 . From the sigmoidal graph that results from such a transformation, the steepness of the slope of the curve called the Hill slope (44) can be obtained graphically. For HDL, the analysis shows the Hill slope to be Ϫ0.76 (95% confidence interval between Ϫ1 and Ϫ0.49), which is not significantly different from the Hill slope of Ϫ1 expected for a single class of binding site on a receptor. Therefore, similar to the results obtained from direct binding of HDL (Fig. 1) , the competitive binding experiments indicate the presence of one class of binding site on SR-BI for HDL.
Competitive binding of apoA-I
Using a similar type of experiment and analysis, the major apolipoprotein on HDL, apoA-I, as a complex with DMPC, is slightly less effective than HDL 3 in competing with 125 I-HDL 3 binding (IC 50 ϭ 45 g protein/ml) ( Table  1) . Interestingly, apoA-I complexed with POPC is a better competitor, with an IC 50 value of 10 g protein/ml. A similar phospholipid-specific effect in the binding of apoA-I to SR-BI has been reported before (20) , suggesting that apoA-I conformation is significant for binding to SR-BI. Consistent with this idea, lipid-free apoA-I is not an effective competitor of 125 I-HDL 3 binding (Fig. 3) . The IC 50 value is 140 g protein/ml, which is over 3-fold higher than that for apoA-I associated with DMPC. As evident from Fig. 3 , lipid-free apoA-I only reduces the binding of 125 I-HDL 3 by ‫,%54ف‬ indicating that even at high concentrations, it cannot fully compete with the binding of 125 I-HDL 3 . Since the apolipoproteins were freshly dialyzed from GdnHCl, they should have remained largely monomeric during the 2 h incubation experiments. This means that the lack of competition is probably not due to loss of effective protein concentration resulting from aggregation or self-association of the ligands. Since lipid-free apoA-I does not achieve full competition, we examined the competitive binding result as follows. If the data are analyzed as the concentration of competitor required to achieve 50% of the maximum inhibition (45% for lipidfree apoA-I and 80% for apoA-I/DMPC), then the resulting transformed IC 50 values are similar ‫52ف(‬ g protein/ ml) for lipid-free apoA-I and apoA-I associated with phospholipid. Interestingly, unlabeled HDL is able to compete effectively with lipid-free 125 I-apoA-I and reduce the binding to ‫%01ف‬ of the control value (data not shown). In control competitive binding experiments, BSA and phospholipid vesicles (Fig. 3) did not inhibit the binding of 125 I-HDL 3 , as others have also shown (23) . These results support the view that SR-BI exhibits a high-affinity protein-protein interaction with apolipoproteins (26) .
Competitive binding of apoA-II and apoE
As seen with apoA-I, other apolipoproteins (i.e., apoA-II and apoE-3) in lipid-free form at high concentrations also reduce the binding of 125 I-HDL 3 by only 45-50% (Fig. 4) . Consistently, lipid-free apolipoproteins have a reduced capacity to compete with HDL for binding to SR-BI. The competitive binding data in Fig. 4 show that similar to apoA-I, apoA-II (Fig. 4A ) and apoE-3 ( Fig. 4B) are both better able to compete with 125 I-HDL 3 binding when added as lipid complexes. Upon complexing with phospholipids, their capacity to reduce 125 I-HDL 3 binding approaches 80% to 85%, equivalent to the reduction caused by unlabeled HDL. Table 1 summarizes the effect of lipid association on the IC 50 values for the major HDL apolipoproteins examined. The data show that the IC 50 values of full-length apolipoproteins decreased from ‫023-031ف‬ g protein/ml to ‫05-53ف‬ g protein/ml upon being associated with phospholipids.
The role of apoE in lipoprotein metabolism is well documented (45), and we wanted to explore further if apoE isoform-specific interaction with SR-BI exists. As seen in Fig. 5 , all three naturally occurring isoforms of apoE can compete effectively with 125 I-HDL 3 . During the preparation of this manuscript, Li et al. (28) reported that the apoE isoforms complexed with phospholipids can bind equally to SR-BI in agreement with our findings. However, our results contradict the recent report by Bultel-Brienne et al. (29) suggesting that lipidated apoE does not bind to SR-BI; the reason for this disagreement is not obvious. The data in Table 1 show that, in the lipid-free state, all three isoforms are not able to compete with 125 I-HDL 3 as effectively as when lipidated. Furthermore, similar to the full-length proteins, each of the 22 kDa apoE molecules (corresponding to N-terminal residues 1-191) compete effectively with 125 I-HDL 3 binding when presented as phospholipid complexes. This indicates that there is a recognition domain present in the N-terminal region of the apoE molecule (28) . Interestingly, as reflected in their IC 50 values (Table 1) , when compared with the full-length molecules, the 22 kDa fragments in the lipid-free state compete poorly with 125 I-HDL 3 . It appears that the C-terminal domain (residues 191-299) is important in enhancing the interaction of lipid-free apoE with SR-BI.
Competitive binding of apoA-I peptides and model peptides
Amino and carboxy terminal deletion mutants of apoA-I can bind to SR-BI (25) , as can the isolated amino and carboxy terminal domains (26) , indicating that more than one domain in the apoA-I molecule can mediate binding to SR-BI. Consistent with these results, Fig. 6A shows that the terminal CNBr fragments of apoA-I complexed with phospholipids are equivalent in their ability to compete with 125 I-HDL 3 for binding to SR-BI. To refine these observations, we performed similar experiments using peptides were in the range of 30 g to 65 g protein/ml; these values are not statistically significantly different (ANOVA P ϭ 0.86). Note that residues 209-241 contain a class Y amphipathic ␣-helix, while residues 1-43 contain a class G* helix (38) . In addition, synthetic amphipathic ␣-helical peptides (18A and 37pA) with no sequence homology to apoA-I as DMPC complexes are effective competitors of 125 I-HDL 3 binding to SR-BI (Fig. 7) ; their IC 50 values are comparable to that of unlabeled HDL 3 . Note that 37pA, which has two helical segments per molecule, exhibits slightly better competition (IC 50 of 10 Ϯ 2.8 vs. 4 Ϯ 1.4 g protein/ml, P ϭ 0.04) than 18A, which contains a single ␣-helix. The results are in agreement with our prior results (26) using the 37pA peptides in cross-linking experiments to show direct interaction of SR-BI and a class A amphipathic ␣-helix. Moreover, peptides of identical sequences containing either all d amino acids or a mixture of D and L enantiomers have the same ability to bind to SR-BI (Fig. 7B) . These results indicate that the binding site in SR-BI is not stereospecific with respect to the handedness of the ␣-helical ligand.
DISCUSSION
A two-step model of SR-BI-mediated selective uptake from a particle such as HDL not only requires binding, but also appropriate organization of the bound HDL and the extracellular domain of the receptor. We demonstrated this previously by showing that apoA-I-mediated selective CE uptake is more efficient than apoE-mediated selective CE uptake in COS-7 cells transfected with SR-BI (18) . The idea of a "productive complex" was also shown in a mutation of apoA-I that exhibited normal binding but a decreased efflux of cholesterol via SR-BI (28). Additionally, HDL from apoA-I-deficient mice binds to SR-BI with the same or greater affinity compared with HDL from wild-type mice, but apoA-I-deficient HDL shows a 2-to 3-fold reduced V max for selective CE uptake (46) . It follows that understanding SR-BI/apolipoprotein interaction is critical for describing the lipid transport process (Step 2, see Appendix) at the molecular level.
Both the phospholipid and protein components of HDL have the potential to bind to the receptor. Thus, Fig. 5 . Competitive binding to SR-BI of 125 I-HDL 3 and apoE isoforms. Y1-BS1 cells were incubated for 2 h at 4ЊC with 10 g/ml of 125 I-HDL 3 plus either apoE-2, apoE-3, or apoE-4 complexed with DMPC. Data points correspond to apoE-2/DMPC complex (triangle), apoE-3/DMPC complex (diamond), and apoE-4/DMPC complex (circle). Data represent mean of triplicate wells Ϯ SD from a representative experiment of five independent experiments. (Fig. 2) (23) , measurements of direct binding showed that the vesicles do bind to SR-BI and that this binding can be inhibited by rHDL (18) . In the case of particles such as HDL, which contain apolipoproteins, the binding to SR-BI is predominately via the apolipoprotein. The experiments with apoA-I peptides (Fig. 6B) , CNBr fragments of apoA-I (Fig. 6A) , apoE isoforms (Fig. 5) (28) , and synthetic amphipathic peptides 18A and 37pA (Fig. 7) indicate that the specific amino acid sequence of an apolipoprotein is not critical for binding to SR-BI, but rather some structural motif common to the exchangeable apolipoproteins is necessary. Our data (Fig. 6A) support and extend the finding that multiple domains of apoA-I can mediate binding to SR-BI (26) .
A particularly important structural motif recognized by SR-BI is the amphipathic ␣-helix in exchangeable apolipoproteins (26) . Presumably, binding of the HDL particles involves interaction of the exposed polar faces of amphipathic ␣-helices in apolipoproteins with SR-BI. The most abundant type of amphipathic ␣-helix present in apolipoproteins is the so-called class A helix, which is characterized by clusters of basic amino acids at the polar-nonpolar interfaces of the helix and acidic residues located at the center of the polar face (47) . Although class A amphipathic ␣-helices interact well with SR-BI (Fig. 7) , binding does not require this particular distribution of charged residues because class Y helices (e.g., apoA-I residues 209-241), defined by having an additional cluster of basic residues in the middle of the polar face, can also mediate binding to SR-BI (Fig. 6) . In comparison, a class G* helix (e.g., apoA-I residues 1-43), which has a random distribution of acidic and basic residues in the polar face, does not bind well to the receptor. The explanation for these differences is not clear at present, but it demonstrates that the subtle variations among the amphipathic ␣-helices of apolipoproteins can modulate interaction with SR-BI. This subtle variation in the helical organization may in part be the molecular explanation for some of the reported differences between apoA-I and apoA-II binding and selective CE uptake (20, 27) , despite the fact that both proteins contain putative amphipathic ␣-helices.
The L-18A and D-18A peptides form right-and lefthanded ␣-helices, respectively, so the distribution of amino acid sidechains along the amphipathic ␣-helix is opposite in the two peptides. The fact that this structural difference does not alter binding to SR-BI (Fig. 7B) is consistent with the observation that a specific sequence of amino acids along the amphipathic ␣-helix is not required. Given that the polar face of a lipidated amphipathic ␣-helix is exposed for potential binding to SR-BI, it seems that the general characteristics of the distribution of charged residues in the polar face of the helix is the feature that is critical for binding. The binding site(s) on the receptor may contain clusters of charged residues that complement the exposed basic and acidic sidechains of amino acids in the amphipathic, ␣-helical ligand. ␣-Helices can function independently in the sense that single helical peptide molecules bind to SR-BI (Fig. 7) , but in proteins such as apoA-I, cooperative interactions of covalently linked helices may be involved in binding to the receptor. This notion is supported by the observation that synthetic peptides composed of 37 amino acids (two ␣-helices) are slightly better at binding to the receptor than those containing only 18 amino acids (one ␣-helix) (Fig. 7A) .
Analysis of HDL direct binding to SR-BI shows a hyperbolic isotherm (Fig. 1) , indicative of a single class of binding sites on the receptor. At first sight, this seems to be inconsistent with the competitive binding data in Table 1 , showing that there are 3-to 10-fold differences in IC 50 values for lipid-free and lipid-associated apolipoproteins. However, the IC 50 values cannot be used simply to derive information about relative affinities of the lipid-free and lipid-associated apolipoproteins for SR-BI, because the maximal degrees of competition are different. Nonetheless, the IC 50 values in Table 1 indicate that the various apolipoproteins compete similarly when they are lipid bound. If the binding site on SR-BI were the same for both lipidated HDL (discoidal rHDL and spherical HDL) and lipid-free apolipoproteins, at some point the lipid-free apolipoproteins should overcome the binding of 125 I-HDL. But this is not the case; lipid-free apolipoproteins bind with reduced capacity, as judged by the limiting ability to complete the binding of 125 I-HDL 3 (Figs. 3, 4) and lower B max (26) , than when they are associated with lipid. This suggests that the binding sites on SR-BI are distinct for lipid-free versus lipidated apolipoprotein. Therefore, our data suggest that the effect of lipidation on apolipoproteins is to increase the amount of binding to the receptor (B max ) and not necessarily to alter the affinity (K d ) of apolipoproteins for the receptor. An explanation for this increase in B max is that multiple apolipoprotein molecules are present on an HDL particle so that, although only a single apolipoprotein molecule may be interacting directly with SR-BI, the other apolipoprotein molecules on the HDL are also bound by virtue of the fact that they are present on the same particle. In the case of lipid-free apolipoproteins, a single molecule in the monomeric state is involved in binding to the receptor.
The current competitive binding data are consistent with a model involving two binding sites on SR-BI, sites A and B. HDL and lipidated apolipoproteins can bind to both sites with equal affinity, while lipid-free apolipoproteins can bind only to site B. Because lipid-free apolipoproteins can bind solely to site B, they can compete for the binding of 125 I-HDL only at this site. Hence, site A is still available for 125 I-HDL to bind. Therefore, the model predicts that the maximum amount by which lipid-free apolipoproteins can compete the binding of 125 I-HDL is 50%, which is consistent with our data. In direct binding experiments, it is not possible to distinguish the second class of binding site since the labeled ligand, be it HDL or lipid-free apolipoproteins, will bind to its binding site irrespective of the other binding sites present. Since the ‫04ف‬ kDa extracellular domain of SR-BI is comparable in size to apoA-I, it is likely that only one apoA-I molecule (either lipid-free or lipidated) can bind to a given receptor molecule at a given time (i.e., sites A and B on the same receptor molecule cannot be occupied simultaneously). This scenario of multiple binding sites is consistent with the observation that lipidated apolipoproteins and HDL can fully compete with lipid free 125 I-apoA-I. Furthermore, other investigators have observed a similar lack of cross competition between HDL and LDL (3), and identified an SR-BI mutant that binds LDL but not HDL (10) . These observations support the idea that there are multiple binding sites on the receptor that can be distinct or overlapping, depending on the type of lipoprotein particle and/or the lipidation state of the apolipoproteins. As the tertiary and quaternary structure (e.g., receptor oligomerization) of SR-BI and fundamental information such as the stoichiometry of interaction between the receptor and the ligand become known, it should be possible to generate a molecular description of the ligand binding site(s) on SR-BI and of how it functions in CE selective uptake.
It was suggested recently that the N-terminal domain of apoE contains the SR-BI binding sequence (28) . However, the situation may be more complicated because the fourhelix bundle structure adopted by the N-terminal domain of the apoE isoforms in the lipid-free state binds less well to the receptor than the full-length apoE molecules, indicating that there is a contribution from the C-terminal region (Table 1) . When complexed with phospholipids, the 22 kDa fragments bind to SR-BI similarly to the full-length proteins (Table 1) . In this situation, the N-terminal fourhelix bundle is open (48) , which shows that the conformation of the apoE molecule significantly affects interaction with SR-BI.
APPENDIX
The scavenger receptor class B, type I (SR-BI)-mediated selective uptake of lipids (L) into cells can be described as a two-step process. The reaction sequence is as follows:
where LD is the lipid-donating particle and LD-R is LD bound to the receptor R (SR-BI).
Step 1 involves a diffusion-dependent binding of LD to R. From the law of mass action and assuming a single class of independent binding sites, the binding (B) of LD to R can be described by the hyperbolic (Scatchard) equation:
where B max is the maximum amount of LD binding (i.e., ng LD bound/mg cell protein) and K d is the equilibrium dissociation constant equal to the ratio of the rate constants k 2 /k 1 . At low LD concentrations (i.e., [LD] ϽϽ K d ), Eq. 3A indicates that B is proportional to [LD] . At concentrations where LD ϾϾ K d , the binding sites are saturated and the amount of LD-R formation is independent of [LD] .
Step 2 involves the dissociation of lipid L from the bound donor particle LD (rate constant ϭ k 3 ), and its diffusion down a concentration gradient into the cell plasma membrane via SR-BI to form D-LR (lipid-depleted donor particle bound to the receptor) (19) . Under initial velocity conditions, this step is essentially irreversible and it is rate limiting (i.e., k 3 Ͻ k 1 ). The rate (V) of selective lipid uptake exhibits a hyperbolic dependence on the concentration of LD.
(Eq. 4A)
This two-step kinetic model of cellular lipid uptake is analogous to the Michaelis-Menten description of the rate of enzyme-substrate interaction and the formation of product. A K m for selective lipid uptake equivalent to the term in the Michaelis-Menten equation can be obtained from the hyperbolic dependence of V on the concentration of LD (Eq. 4A). The experimentally derived values of K d and K m are similar (Fig. 1) , indicating that steps 1 and 2 are coupled.
If the binding of donor particle LD to SR-BI is mediated by an apolipoprotein, step 2 leads to the selective transfer of lipid molecules from the LD-R complex to the cell membrane. If LD contains different classes of lipid, the relative rates of selective uptake of these lipids are determined by the values of the rate constants (k 3 ) defining their dissociation from the bound LD. www.jlr.org
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nor particle LD to SR-BI is not mediated by an apolipoprotein. When the binding of the donor particle LD to SR-BI is mediated by the lipid component L, the selectivity of lipid uptake disappears. The rate constant k 3 , defining the dissociation of lipid molecules from LD, is no longer relevant and is replaced by the rate constant describing the cellular uptake of intact LD. The molecular mechanism of the latter process is consistent with an SR-BI-mediated fusion of the donor lipid particle and the cell plasma membrane (18) .
